This site is a resource for the cancer community. Our goal is to create a functional model of cancer using a
collection of cancer cells. We have catalogued the genomic and molecular properties of a panel of breast cell
lines and demonstrated a fidelity to those found in primary breast tumors. Recurrent genome aberrations and the
resulting transcriptional changes are well preserved in the cell line collection. This provides a platform to
develop candidate response predictors/indicators to guide early phase clinical trials, identify therapeutic
agents that may be effective when used in combination and/or reveal molecular mechanisms of resistance. Continuing
characterization of these cell lines, development of more cell lines and more realistic cell culture environments
and assessment of multiple aberration-targeted agents should provide an increasingly useful resource for assessment
of how genome aberrations contribute to breast cancer pathophysiology.
Latest News
Jun. 25, 2007
Joe Gray Named Breast Cancer Research Innovator Joe Gray is a "named awardee" of an Innovator Award from the Breast Cancer Research Program of the Department of Defense, the world's second-largest funding agency for breast cancer research. Gray's proposal, "Early Detection of Metastasis-Prone Breast Cancers," aims to catch more breast tumors before they metastasize by improving mammography and routine procedures. Details of the multimillion-dollar award will be announced when final.
Apr. 20, 2007
LBNL Breast Cancer Biomarker Research gets AACR news coverage: (http://www.newswise.com/articles/view/528829/)Apr. 20, 2007
Joe Gray discusses cancer biomarker discovery on ABC news. (http://abclocal.go.com/kgo/story?section=drive_to_discover&id=5219796)Apr. 20, 2007
Dr. Ying Guan and Dr. Zhi Hu present in Minisymposia at AACR annual meetingDec. 13, 2006
Breast cancer pathophysiology papers published in December Cancer Cell (http://www.cancercell.org/)